한글목차

배란 유도제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 47억 달러에서 2026년에는 50억 달러에 이르고, CAGR 6.2%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 불임 유병률 증가, 생식 건강에 대한 인식 개선, 다낭성난소증후군(PCOS) 발생률 증가, 불임 치료 클리닉 접근성 개선, 보조생식술 기술 확대 등을 들 수 있습니다.

배란 유도제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 66억 2,000만 달러에 이르고, CAGR은 7.3%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 출산 연령 지연 추세, 여성 노동력 참여율 증가, 저침습적 불임 치료 수요 증가, 여성 헬스케어 분야의 의료비 지출 증가, 신흥국의 불임 치료 접근성 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 1차 선택 경구용 배란유도제 사용 증가, 개별화된 불임 치료 프로토콜 선호도 증가, 병용요법 채택 확대, 다낭성난소증후군(PCOS) 관리에 배란유도제 사용 확대, 조기 불임 진단 및 치료로의 전환 등을 들 수 있습니다.

여성 불임의 유병률 증가는 향후 몇 년 동안 배란유도제 시장의 성장을 견인할 것으로 예측됩니다. 여성 불임은 정기적인 피임 없이 약 1년 이상 성관계를 지속했음에도 불구하고 임신을 할 수 없거나 임신을 유지할 수 없는 생물학적 상태를 말합니다. 이 상태는 배란 기능 장애, 호르몬 균형 장애, 기타 자연 임신을 방해하는 생식 건강상의 합병증과 관련이 있는 경우가 많습니다. 배란유도제는 배란을 조절하는 호르몬 경로를 자극하고 성숙한 난자의 방출을 촉진하여 임신을 지원함으로써 이러한 문제를 해결합니다. 예를 들어, 2023년 4월 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)가 발표한 자료에 따르면, 전 세계 성인 인구의 약 17.5%(약 6명 중 1명)가 일생 동안 불임을 경험하고 있습니다. 따라서 여성 불임 증가 추세가 배란유도제 시장의 성장을 견인하고 있습니다.

배란유도제 시장에서 사업을 전개하고 있는 주요 기업들은 혁신적이고 보다 접근하기 쉬운 불임 치료제를 개발하기 위해 전략적 제휴를 추진하고 있습니다. 이번 전략적 제휴를 통해 양사는 전문 지식을 통합하고, 자원을 공유하며, 개발 비용을 절감하고, 전 세계 환자들을 위한 보다 진보적이고 합리적인 가격의 불임 치료제 시장 출시를 가속화함으로써 시장 성장을 가속할 수 있을 것으로 기대됩니다. 예를 들어, 2023년 10월, 미국 제약회사 코젯 파마슈티컬스(Coset Pharmaceuticals)는 미국 온라인 약국 마크 쿠바 코스트플러스 드럭(Mark Cuban Cost Plus Drugs)과 제휴하여 환자들에게 보다 저렴한 가격으로 클로미드(R)(클로미펜 구연산염)를 제공할 수 있게 되었습니다. 보다 저렴한 가격으로 제공할 수 있게 되었습니다. 이번 제휴는 코젯의 불임치료제 관련 전문성과 코스트플러스 드럭의 투명하고 저렴한 가격 책정 모델을 활용하여 환자들의 접근성을 확대하기 위한 것입니다. 경제적 장벽을 낮춤으로써 치료 지속률을 높이고, 전 세계적으로 불임 치료를 원하는 더 많은 사람들을 지원하는 것을 목표로 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Ovulation-inducing drugs are medications used to stimulate the ovaries and promote the release of mature eggs (ovulation) in women who have irregular menstrual cycles or face infertility issues. These drugs work by influencing the hormonal balance in the body, specifically targeting the hormones that regulate ovulation.

The main types of ovulation-inducing drugs include hormones and therapeutic drugs. Hormone drugs are medications designed to alter or mimic the effects of naturally occurring hormones in the body. They can be administered via oral, topical, and other routes and are used by a range of end users, including hospitals, homecare providers, specialty clinics, and others.

Tariffs have influenced the ovulation inducing drugs market by increasing costs associated with active pharmaceutical ingredients, hormones, and injectable formulations that rely on cross-border supply chains. These impacts are more pronounced in hormone-based and parenteral drug segments, with Asia-Pacific and parts of Europe being most affected due to their role in pharmaceutical manufacturing and exports. Higher tariffs have led to pricing pressure and margin constraints for manufacturers and fertility clinics. However, tariffs have also encouraged local production, contract manufacturing partnerships, and supply chain diversification, supporting long-term market resilience.

The ovulation inducing drugs market research report is one of a series of new reports from The Business Research Company that provides ovulation inducing drugs market statistics, including ovulation inducing drugs industry global market size, regional shares, competitors with a ovulation inducing drugs market share, detailed ovulation inducing drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovulation inducing drugs industry. This ovulation inducing drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.7 billion in 2025 to $5 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of infertility disorders, increasing awareness of reproductive health, growing incidence of pcos, improved access to fertility clinics, expansion of assisted reproductive technologies.

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to delayed childbearing trends, increasing female workforce participation, rising demand for minimally invasive fertility treatments, growing healthcare expenditure on women health, expanding access to fertility treatments in emerging economies. Major trends in the forecast period include rising use of first-line oral ovulation inducers, growing preference for personalized fertility protocols, increasing adoption of combination drug therapies, expanding use of ovulation drugs in pcos management, shift toward early infertility diagnosis and treatment.

The increasing prevalence of women's infertility is expected to drive the growth of the ovulation-inducing drug market in the coming years. Women's infertility is a biological condition in which a woman is unable to conceive or carry a pregnancy to term despite engaging in regular, unprotected sexual intercourse for about a year or longer. This condition is often linked to ovulatory dysfunction, hormonal imbalances, and other reproductive health complications that hinder natural conception. Ovulation-inducing drugs help address these issues by stimulating the hormonal pathways that regulate ovulation and promoting the release of mature eggs to support pregnancy. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 17.5% of the global adult population-about 1 in 6 individuals-experience infertility during their lifetime. Therefore, the rising prevalence of women's infertility is driving the growth of the ovulation-inducing drug market.

Major companies operating in the ovulation-inducing drugs market are pursuing strategic partnerships to develop innovative and more accessible fertility treatments. Strategic partnerships drive market growth by enabling companies to combine expertise, share resources, reduce development costs, and accelerate the launch of advanced and more affordable fertility therapies for patients worldwide. For instance, in October 2023, Cosette Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Mark Cuban Cost Plus Drug Company, a US-based online pharmacy, to make CLOMID(R) (clomiphene citrate) more affordable for patients. This collaboration leverages Cosette's expertise in fertility medications and Cost Plus Drug Company's transparent, low-cost pricing model to expand patient access. By reducing financial barriers, the partnership aims to improve treatment adherence and support more individuals seeking fertility care globally.

In February 2024, Novo Holdings, a Denmark-based life sciences investment company, acquired Catalent Inc. for $16.5 billion. Through this acquisition, Novo Holdings aims to enhance its drug development and manufacturing capabilities by leveraging Catalent's expertise in advanced formulation, biologics production, gene therapies, and specialized drug delivery technologies. This strategic move is intended to accelerate innovation, streamline development processes, and expand Novo Holdings' global presence in high-growth therapeutic areas. Catalent Inc. is a US-based pharmaceutical company that manufactures a range of drug products, including ovulation-inducing drugs.

Major companies operating in the ovulation inducing drugs market are Ferring Pharmaceuticals Inc., EMD Serono Inc., Merck And Co. Inc., Gedeon Richter plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc., LIVZON Pharmaceutical Group Inc.

North America was the largest region in the ovulation-inducing drugs market in 2025. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ovulation inducing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ovulation-inducing drugs market consists of sales of clomiphene citrate (Clomid), letrozole (Femara), gonadotropins, human chorionic gonadotropin (hCG), bromocriptine (Cycloset, Parlodel). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovulation Inducing Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ovulation inducing drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovulation inducing drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ovulation inducing drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Hormones; Therapeutics Drugs
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By End-User: Hospital; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Hormones: Gonadotropins; Clomiphene Citrate; Aromatase Inhibitors
• 2) By Therapeutic Drugs: Metformin; Letrozole; Bromocriptine
• Companies Mentioned: Ferring Pharmaceuticals Inc.; EMD Serono Inc.; Merck And Co. Inc.; Gedeon Richter plc; Pfizer Inc.; Novartis AG; Bayer AG; Sanofi SA; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Astellas Pharma Inc.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Dr Reddy's Laboratories Ltd.; Intas Pharmaceuticals Limited; Lupin Limited; Torrent Pharmaceuticals Ltd.; Glenmark Pharmaceuticals Ltd.; Zydus Pharmaceuticals (USA) Inc.; LIVZON Pharmaceutical Group Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Ovulation Inducing Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Ovulation Inducing Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Ovulation Inducing Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Ovulation Inducing Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Rising Use Of First-Line Oral Ovulation Inducers
  • 4.2.2 Growing Preference For Personalized Fertility Protocols
  • 4.2.3 Increasing Adoption Of Combination Drug Therapies
  • 4.2.4 Expanding Use Of Ovulation Drugs In Pcos Management
  • 4.2.5 Shift Toward Early Infertility Diagnosis And Treatment

5. Ovulation Inducing Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Fertility Clinics
• 5.4 Ambulatory Surgical Centers
• 5.5 Research Institutes

6. Ovulation Inducing Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ovulation Inducing Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Ovulation Inducing Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Ovulation Inducing Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Ovulation Inducing Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Ovulation Inducing Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ovulation Inducing Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ovulation Inducing Drugs Market Segmentation

• 9.1. Global Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hormones, Therapeutics Drugs
• 9.2. Global Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Routes Of Administration
• 9.3. Global Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital, Homecare, Specialty Clinics, Other End-Users
• 9.4. Global Ovulation Inducing Drugs Market, Sub-Segmentation Of Hormones, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors
• 9.5. Global Ovulation Inducing Drugs Market, Sub-Segmentation Of Therapeutic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Metformin, Letrozole, Bromocriptine

10. Ovulation Inducing Drugs Market Regional And Country Analysis

• 10.1. Global Ovulation Inducing Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Ovulation Inducing Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ovulation Inducing Drugs Market

• 11.1. Asia-Pacific Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ovulation Inducing Drugs Market

• 12.1. China Ovulation Inducing Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ovulation Inducing Drugs Market

• 13.1. India Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ovulation Inducing Drugs Market

• 14.1. Japan Ovulation Inducing Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ovulation Inducing Drugs Market

• 15.1. Australia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ovulation Inducing Drugs Market

• 16.1. Indonesia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ovulation Inducing Drugs Market

• 17.1. South Korea Ovulation Inducing Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ovulation Inducing Drugs Market

• 18.1. Taiwan Ovulation Inducing Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ovulation Inducing Drugs Market

• 19.1. South East Asia Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ovulation Inducing Drugs Market

• 20.1. Western Europe Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ovulation Inducing Drugs Market

• 21.1. UK Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ovulation Inducing Drugs Market

• 22.1. Germany Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ovulation Inducing Drugs Market

• 23.1. France Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ovulation Inducing Drugs Market

• 24.1. Italy Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ovulation Inducing Drugs Market

• 25.1. Spain Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ovulation Inducing Drugs Market

• 26.1. Eastern Europe Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ovulation Inducing Drugs Market

• 27.1. Russia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ovulation Inducing Drugs Market

• 28.1. North America Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ovulation Inducing Drugs Market

• 29.1. USA Ovulation Inducing Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ovulation Inducing Drugs Market

• 30.1. Canada Ovulation Inducing Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ovulation Inducing Drugs Market

• 31.1. South America Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ovulation Inducing Drugs Market

• 32.1. Brazil Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ovulation Inducing Drugs Market

• 33.1. Middle East Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ovulation Inducing Drugs Market

• 34.1. Africa Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Ovulation Inducing Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ovulation Inducing Drugs Market Regulatory and Investment Landscape

36. Ovulation Inducing Drugs Market Competitive Landscape And Company Profiles

• 36.1. Ovulation Inducing Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Ovulation Inducing Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Ovulation Inducing Drugs Market Company Profiles
  • 36.3.1. Ferring Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. EMD Serono Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Gedeon Richter plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Ovulation Inducing Drugs Market Other Major And Innovative Companies

• Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc., LIVZON Pharmaceutical Group Inc.

38. Global Ovulation Inducing Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Ovulation Inducing Drugs Market

40. Ovulation Inducing Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Ovulation Inducing Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Ovulation Inducing Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Ovulation Inducing Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer